SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Piramal Pharma - Quaterly Results

28 Jan 2025 Evaluate
The company witnessed a 21.89% growth in the revenue at Rs. 12483.20 millions for the quarter ended December 2024 as compared to Rs. 10241.40 millions during the year-ago period.Profit after tax for the quarter ended December 2024 reported a huge growth of 59.81% to Rs. 1188.00  millions from Rs. 743.40 millions.The company reported a good operating profit of 2440.40 millions compared to 1586.40 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 12483.20 10241.40 21.89 35959.10 28648.10 25.52 43901.10 34432.20 27.50
Other Income 247.00 331.10 -25.40 1678.40 1488.70 12.74 2020.60 3410.70 -40.76
PBIDT 2440.40 1586.40 53.83 7917.00 3771.50 109.92 8199.80 4386.00 86.95
Interest 291.70 174.20 67.45 840.00 794.40 5.74 1071.00 1158.70 -7.57
PBDT 2148.70 1412.20 52.15 7077.00 2977.10 137.71 7128.80 3157.70 125.76
Depreciation 554.60 515.60 7.56 1609.20 1527.60 5.34 2052.60 1920.80 6.86
PBT 1594.10 896.60 77.79 5467.80 1449.50 277.22 5076.20 1236.90 310.40
TAX 406.10 153.20 165.08 1326.50 268.10 394.78 1164.00 541.90 114.80
Deferred Tax -2.20 -21.80 -89.91 27.60 15.70 75.80 39.20 154.20 -74.58
PAT 1188.00 743.40 59.81 4141.30 1181.40 250.54 3912.20 695.00 462.91
Equity 13235.80 13229.50 0.05 13235.80 13229.50 0.05 13229.50 11933.20 10.86
PBIDTM(%) 19.55 15.49 26.21 22.02 13.16 67.24 18.68 12.74 46.63

Piramal Pharma Share Price

148.90 1.45 (0.98%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×